Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes
Status:
Completed
Trial end date:
2019-02-21
Target enrollment:
Participant gender:
Summary
The mainstay for treatment for acute coronary syndrome (ACS) focusses on re-establishing and
maintaining the patency of vessels following coronary plaque disruption, through the use of
anti-platelets and anticoagulants. Despite advances in management ACS still carries a high
risk of morbidity and mortality, thus future management is likely to target other pathways.
Recent studies indicate that CD4+ T cells, and more specifically Treg cells, are important
for the control of post-ischemic immune responses and the promotion of myocardial healing.
The investigators therefore hypothesise that expansion of Treg cells in patients with ACS
dampens the activation of the immune response and promotes both plaque and myocardial
healing. The investigators hypothesise that this can be achieved through subcutaneous
administration of low doses of interleukin-2 (IL-2). IL-2 supplementation appears to be an
attractive therapeutic option playing a key role in Treg cell development, expansion,
survival and suppressive function.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust